COMMUNIQUÉS West-GlobeNewswire

Solana Company Announces Positions and Votes on first Solana Governance Proposals
21/08/2026
PHILADELPHIA, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT), a listed digital asset treasury company and operator of institutional Solana validator infrastructure across Asia-Pacific, today announced [...]
Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease Patients
21/08/2026
Investment supports launch of AI care companion, Ella, designed to help Lyme+ patients navigate diagnosis, treatment, and long-term disease management PORTOLA VALLEY, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Bay Area [...]
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
21/08/2026
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and [...]
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
21/08/2026
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel [...]
Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy
21/08/2026
ADELAIDE, Australia, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim [...]
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
21/08/2026
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
21/08/2026
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
21/08/2026
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular [...]
Synergy CHC Corp. Announces Receipt of Nasdaq Letter
21/08/2026
N. WINDHAM, Maine, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, today announced that it received a notice (the “Notice”) from [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
21/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/08/2026
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing [...]
SK pharmteco participera au salon CPHI et présentera ses capacités de CDMO multimodales ainsi que son infrastructure mondiale de fabrication
21/08/2026
Les dirigeants et experts techniques de l’entreprise présenteront des solutions intégrées de bout en bout pour les petites molécules et les vecteurs viraux SK pharmteco est sponsor officiel du CPHI Sustainability Summit [...]
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
21/08/2026
REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a [...]
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
21/08/2026
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Kylo Peptides Publishes Report on the Verification Gap Reshaping the Research Peptide Market in 2026
21/08/2026
Kylo Peptides' "State of Research Peptides 2026" documents a widening gap between label claims and vial contents, and argues that third-party verification, not a purity percentage, is the only reliable signal of quality [...]
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
21/08/2026
Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens 1 This immunotherapy doublet regimen demonstrated [...]
Ipsen finalise l'acquisition de Kartos Therapeutics, renforçant son portefeuille d'oncologie en phase avancée
21/08/2026
PARIS, FRANCE, 21 AOUT 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui avoir finalisé l'acquisition de Kartos Therapeutics, une société biopharmaceutique au stade clinique, apportant le navtemadlin, un [...]

Pages